Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study-Reference-Cited by-同舟云学术

Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study

Published:2024-09-07 Issue: Volume: Page:
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wei Yujun,Qian Kun,Le Ning,Wang Lili,Li Fei,Luan Songhua,Wang Lu,Jin Xiangshu,Peng Bo,Wang Nan,Dou Liping,Liu Daihong

Funder

National Natural Science Foundation of China

Beijing Natural Science Foundation of China

Beijing Nova Program

National Key Research and Development Program of China

Military medical support innovation and generate special program

Special Research Found for Health Protection

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05972-w.pdf

Reference42 articles.

1. Lulla PD, Naik S, Vasileiou S et al (2021) Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood 137(19):2585–2597. https://doi.org/10.1182/blood.2020009471

2. Tsai SB, Rhodes J, Liu H et al (2018) Reduced-intensity allogeneic transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome using combined CD34-Selected Haploidentical Graft and a single umbilical cord unit compared with matched unrelated donor stem cells in older adults. Biol Blood Marrow Transpl 24(5):997–1004. https://doi.org/10.1016/j.bbmt.2017.12.794

3. Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62–70. https://doi.org/10.1182/blood-2015-07-604546

4. Molica M, Breccia M, Foa R, Jabbour E, Kadia TM (2019) Maintenance therapy in AML: the past, the present and the future. Am J Hematol 94(11):1254–1265. https://doi.org/10.1002/ajh.25620

5. Gao L, Zhang Y, Wang S et al (2020) Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse of patients with high-risk MRD-Negative AML after HSCT: an Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol 38(36):4249–4259. https://doi.org/10.1200/JCO.19.03277